GSK Aims for £40B Sales by 2031 Under New CEO Luke Miels
GSK, under the leadership of incoming CEO Luke Miels, aims to reach over £40 billion in total sales by 2031. The pharmaceutical giant has transformed its research and development, with 15 major pipeline opportunities set to launch in the coming years.
GSK has focused on specialty medicines and vaccines, introducing several new products to the market under Dame Emma Walmsley's tenure. Miels, who will take over from Walmsley in January 2026, has played a significant role in building GSK's portfolio, particularly in oncology and respiratory areas.
GSK's share price has surged 11% to 1654.5p following the announcement of Miels' appointment, giving the company a market cap of £67.2bn. Miels, who joined GSK in 2017 as chief commercial officer, brings over three decades of industry experience, previously serving as executive vice president of AstraZeneca.
GSK's ambitious sales target and pipeline opportunities signal a promising future under Miels' leadership. The company's focus on specialty medicines and vaccines, coupled with Miels' extensive experience, positions GSK for continued growth and success on the stock market today.
Read also:
- Industrial robots in China are being installed at a faster rate than in both the United States and the European Union, as the global market for these robots faces a downturn.
- Undeads Games Reaches $30 Million TVL and Gears Up for MMORPG Debut
- Hyundai N affirms transition to hybrid performance-centric models, initiating with Tucson N
- Bank of America reveals investigation into Zelle platform, hints at potential legal action
